Atea Corp (AVIR) - Long-Term Debt to Capital Coefficient

Atea Corp - graphic logo of issuer AVIR

The manufacturer's dependence on Asian raw material supplies and geopolitical complexities during drug trials coexist with the implementation of ESG waste disposal standards and cold chain optimization. This chart of the market value demonstrates the 0.00 indicator. Atea Pharmaceuticals (AVIR) is currently actively developing its hepatitis C portfolio, creating innovative therapy methods within the framework of ongoing clinical trials.

Atea Pharma (AVIR): Long-Term Debt to Equity from 07/04/2022 to 10/29/2026

Comprehensive metric breakdowns and analytics for Atea Pharmaceuticals (AVIR)

- stock price and consensus target price:
Quote Chart Atea Pharma|AVIR - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Atea Pharmaceuticals, Inc.|AVIR - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Atea Pharmaceuticals|AVIR - Company Book Value|Market Value to Book Value ateapharma.com|AVIR - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Atea Pharmaceuticals|AVIR - Long-Term Debt to Capital|Short-Term Debt to Capital ateapharma.com|AVIR - Company Total Debt|Debt to Net Assets Ratio Atea Pharmaceuticals, Inc.|AVIR - Company Long-Term Liabilities|Company Short-Term Debt Atea Pharmaceuticals|Interim Coverage Ratio ateapharma.com
- net income and valuation ratios data:
AVIR - Company Net Income
General company analysis:Atea Pharma - AVIR
Signature product of Atea Pharmaceuticals

An investment audit of Atea Pharmaceuticals (AVIR) requires an assessment of financial leverage via the ratio of liabilities with a maturity of over one year to equity. This metric measures the company's reliance on debt financing, which is critical for Atea Pharmaceuticals, as it has minimized capital expenditures by utilizing external CDMO facilities, a factor reflected in the long-term debt-to-equity trend.

Competing companies

Gilead - Long-Term Liabilities to Equity|Long-Term Debt to Capital CDTX|NVAX (Novavax Pharma) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CVAC (CureVac N.V.)|Long-Term Debt to Capital valneva.com VALN|VIR - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient SIGA (SIGA Technologies Inc)|Emergent Corp (EBS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Invivyd|ENTA (Enanta Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital inovio.com|Long-Term Debt to Equity Ratio HLVX (HilleVax)|KLRS (Kalaris Therapeutics Inc.) - Long-Term Debt to Capital Coefficient|Dyadic International, Inc. - Long-Term Debt to Equity Ratio|NanoViricides Inc. - Long-Term Debt to Equity|Talphera, Inc. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital cocrystalpharma.com COCP|trawspharma.com (TRAW) - Long-Term Debt to Equity|Dogwood Therapeutics - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio QLGN|Long-Term Debt to Capital AlloVir Bio|Long-Term Debt to Equity VBI Vaccines Inc. (VBIV)|Ratio of Long-Term Indebtedness to Capital virios.com|Long-Term Debt to Capital VXRT (Vaxart)